The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
1. A vaccine composition for immunizing a porcine animal against infection by Mycoplasma hyopneumoniae and a viral pathogen which comprises
an immunizing amount of a Mycoplasma hyopneumoniae bacterin;
an immunizing amount of at least one bacterial or viral antigen selected from the group consisting of Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae , leptospira bacteria, swine influenza virus (SIV), porcine reproductive and respiratory syndrome virus (PRRSV), and porcine circovirus (PCV);
at least one adjuvant; and
a pharmaceutically acceptable carrier which vaccine composition after a single administration elicits protective immunity from Mycoplasma hyopneumoniae.
2. The vaccine composition of claim 1 , further comprising a bacterial or viral antigen selected from one or more of the following groups, SIV; Haemonphilus parasuis ; the group consisting of PRRSV and PCV; the group consisting of SIV and Erysipelothrix rhusiopathiae : the group consisting of Pasteurella multiocida and Bordetella bronchiseptica.